Printer Friendly

BRISTOL-MYERS SQUIBB COMPANY OBTAINS WORLDWIDE RIGHTS TO SONORX(R), AN ORAL ULTRASOUND CONTRAST AGENT

 PRINCETON, N.J., Nov. 29 /PRNewswire/ -- Bristol-Myers Squibb Company (NYSE: BMY) today announced that it has acquired exclusive worldwide rights to manufacture and market a new oral ultrasound contrast agent under the trade name SonoRx(R) (simethicone coated cellulose).
 Bristol-Myers Squibb Company had previously acquired the North American rights to SonoRx through a separate in-licensing agreement with ImaRx Pharmaceutical Corp. of Tucson, Ariz., which discovered the product. The worldwide rights were obtained through European and Japanese licensing agreements recently signed by Bristol-Myers Squibb Company and ImaRx.
 SonoRx represents a new class of diagnostic imaging products that may be used by a broad range of medical practitioners who perform abdominal ultrasound procedures. SonoRx may allow physicians to see internal organs more easily by eliminating the gas artifacts that can prevent clear delineation of structures in the region of interest. Administered shortly before an ultrasound examination, SonoRx may aid in diagnosing gastrointestinal, pancreatic and liver disease.
 "We are delighted to be the exclusive worldwide manufacturer and distributor of SonoRx(R), which we anticipate will have a significant impact in the diagnostic market," said Dr. Brian Gallagher, vice president and general manager of Squibb Diagnostics, the Bristol-Myers Squibb company that will market SonoRx. He added, "We believe that SonoRx will satisfy a currently unmet clinical demand for more reliable depiction of gastrointestinal anatomy when using ultrasound techniques." More than 133 million diagnostic ultrasound procedures were performed throughout the world in 1991, including more than 61 million in the United States.
 Bristol-Myers Squibb Company already has submitted an Investigational New Drug (IND) application for SonoRx, and clinical trials have been initiated and are expected to be completed soon. SonoRx will be manufactured by Westwood-Squibb Pharmaceuticals, a Bristol-Myers Squibb company, at a plant located in Buffalo, N.Y.
 Bristol-Myers Squibb Company is a research-based, diversified healthcare company whose principal businesses are pharmaceuticals, consumer products, nutritionals and medical devices. It is among the world's leading makers of cardiovascular, anti-cancer, anti-infective, central nervous system and dermatological drug therapies, diagnostic agents and non-prescription medicines.
 /delval/
 -0- 11/29/93 R
 /CONTACT: Patrick D. Donohue of Bristol-Myers Squibb Company, 609-252-5685/
 (BMY)


CO: Bristol-Myers Squibb Company; ImaRx Pharmaceutical Corp.;
 Westwood-Squibb Pharmaceuticals ST: New Jersey, Arizona, New York IN: MTC SU:


MP -- PH005R -- 8220 11/29/93 11:10 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 29, 1993
Words:379
Previous Article:TURNSTONE AND OFFICE DEPOT FORM MARKETING ALLIANCE TO BRING OFFICE FURNISHINGS AND SERVICES TO ATLANTA'S SMALL BUSINESSES, HOME OFFICES
Next Article:STERIS CORPORATION CREATES NEW OPERATING DIVISIONS TO MANAGE RAPID GROWTH
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters